Methods for deformulating drugs

October 25, 2018

The FDA has a number of regulatory routes through which a company can seek approval for a generic drug. The most notable is the Abbreviated New Drug Application (ANDA) route whereby a generic company develops an exact copy of the innovator product and can use the safety and efficacy data from the innovator in their submission. This route was facilitated in the 1980s through the Drug Price Competition and Patent Term Restoration Act, informally known as the Hatch-Waxman Act after Senator Orrin Hatch and Representative Henry Waxman who sponsored it. The US government at the time were concerned about the low number of generic drug approvals. Before the Hatch-Waxman act, innovator companies could easily create legal obstacles for companies looking to develop generic medicines; this made generic drug development an unattractive industry. The Hatch-Waxman Act removed many of these obstacles, successfully incentivising generics companies to produce affordable generic medicines, whilst simultaneously protecting innovator companies by allowing them a sufficient exclusivity period after the initial release of their drug and keep innovation profitable.

Spotlight

Nivalis Therapeutics, Inc.

Nivalis Therapeutics (formerly N30 Pharmaceuticals) is headquartered in Boulder, Colorado. Our company is small, but passionate and growing. We have transitioned from an early-stage company focused on preclinical exploration.

OTHER WHITEPAPERS
news image

The Ultimate Guide to Digitizing Pharma Manufacturing

whitePaper | September 15, 2022

The sheer size of the pharmaceutical industry makes it important for all stakeholders to stay up to date with pharmaceutical industry trends.

Read More
news image

Coronavirus (COVID-19) and Its Effect on Pharmaceutical Marketing and Sales

whitePaper | March 16, 2020

With the rapid onset of coronavirus in the United States, many pharma companies are being forced to prepare for a scenario in which their reps cannot visit providers and patients are limited in their ability to visit their healthcare professionals (HCP). The CDC has gone as far as recommending the use of telemedicine and patient portals as primary channels for HCPs and patients to interact.

Read More
news image

A BLOCKCHAIN TO ENSURE COUNTERFEIT FREE PHARMACEUTICAL SUPPLY CHAIN

whitePaper | February 5, 2022

Essential medicine access is one of the main objectives of healthcare systems in and pharmaceutical supply chains ensure that the right amount of medicine, with acceptable quality, will reach the customers in need

Read More
news image

Multi-channel clinical trial recruitment technology checklist

whitePaper | August 8, 2022

Biopharma R&D professionals generally admit that the current "high-cost, high-risk" development model is unsustainable. Despite technological.

Read More
news image

Pharmaceutical Sales Strategies Post-COVID-19: The Benefits of Virtual Engagement

whitePaper | April 7, 2021

In less than a week, in the face of a pandemic, the pharmaceutical sales model changed forever. In-person healthcare provider (HCP) visits came to a screeching halt and brand marketers scrambled to find ways to educate and engage these providers remotely. While the pandemic may have taken us by surprise, we should acknowledge that, even before the pandemic, pharmaceutical sales teams faced significant challenges. One solution for these challenges is to engage HCPs – virtually.

Read More
news image

Global Use of Medicines 2023

whitePaper | January 18, 2023

Reaching a post-pandemic era is an alluring prospect for almost everyone around the world after the disruptions of the past three years.

Read More

Spotlight

Nivalis Therapeutics, Inc.

Nivalis Therapeutics (formerly N30 Pharmaceuticals) is headquartered in Boulder, Colorado. Our company is small, but passionate and growing. We have transitioned from an early-stage company focused on preclinical exploration.

Events